This database contains 750 studies, archived under the term: "aged, 80 and over"
Click here to filter this large number of results.
Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-AD
Vigen, Cheryl L. P.,
Mack, Wendy J.,
Keefe, Richard S. E.,
Sano, Mary,
Sultzer, David L.,
Stroup, T. Scott,
Dagerman, Karen S.,
Hsiao, John K.,
Lebowitz, Barry D.,
Lyketsos, Constantine G.,
Tariot, Pierre N.,
Zheng, Ling,
Schneider, Lon S.
Objective: The impact of the atypical antipsychotics olanzapine, quetiapine, and risperidone on cognition in patients with Alzheimer’s disease is unclear. The authors assessed the effects of time and treatment on neuropsychological functioning during the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s Disease study (CATIE-AD).; Method: CATIE-AD included 421 outpatients with Alzheimer’s disease and psychosis or agitated/aggressive […]
Effect of Rikkunshi-to on appetite loss found in elderly dementia patients: a preliminary study
Utumi, Yushi,
Iseki, Eizo,
Murayama, Norio,
Nozawa, Motohiro,
Kumagai, Ryo,
Matsubara, Youichiro,
Ichimiya, Yosuke,
Arai, Heii
Background: Functional gastrointestinal symptoms are frequently found in elderly dementia patients. In such a case, we attempt treatment by the administration of antidepressants or second-generation antipsychotics. However, these medications have a risk of side-effects. In the present study, we carried out oral administration of Rikkunshi-to to elderly dementia patients with appetite loss, and examined its […]
Systematic care for caregivers of patients with dementia: a multicenter, cluster-randomized, controlled trial
Spijker, Anouk,
Wollersheim, Hub,
Teerenstra, Steven,
Graff, Maud,
Adang, Eddy,
Verhey, Frans,
Vernooij-Dassen, Myrra
Objective: To evaluate the effectiveness of the Systematic Care Program for Dementia (SCPD) on patient institutionalization and to determine the predictors of institutionalization.; Design: Single-blind, multicenter, cluster-randomized, controlled trial.; Setting: Six community mental health services (CMHSs) across the Netherlands.; Participants: A total of 295 patient-caregiver dyads referred to a CMHS with suspected patient dementia.; Intervention: […]
Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer’s disease: results of a 16-week open-label trial
Schulz, Jörg B.,
Rainer, Michael,
Klünemann, Hans-Hermann,
Kurz, Alexander,
Wolf, Stefanie,
Sternberg, Kati,
Tennigkeit, Frank
The present study evaluated the effects of once-daily memantine (20 mg) treatment on cognition and communication in patients with moderate to severe Alzheimer’s disease (AD). In a multicenter, single-arm open-label study, outpatients diagnosed with AD (MMSE < 20; n = 97) were titrated from 5 mg to 20 mg once-daily memantine over 4 weeks. Once-daily […]
An MRI substudy of a donepezil clinical trial in mild cognitive impairment
Schuff, Norbert,
Suhy, Joyce,
Goldman, Robert,
Xu, Yikang,
Sun, Yijun,
Truran-Sacrey, Diana,
Murthy, Anita
A magnetic resonance imaging (MRI) study was conducted as part of an intervention study in subjects with amnestic mild cognitive impairment (aMCI) to assess donepezil’s treatment effect on brain atrophy. Adults with aMCI were randomly assigned to double-blind treatment with 10 mg/day donepezil hydrochloride or placebo for 48 weeks. Brain MRI scans were acquired at […]
The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease: a randomized controlled trial
Sato, Yoshihiro,
Honda, Yoshiaki,
Umeno, Kazuo,
Hayashida, Norimasa,
Iwamoto, Jun,
Takeda, Tsuyoshi,
Matsumoto, Hideo
A high incidence of fractures, particularly of the hip, represents an important problem in patients with Alzheimer disease (AD), who are prone to falls and have osteoporosis. We previously found that vitamin K deficiency and low 25-hydroxyvitamin D (25-OHD) with compensatory hyperparathyroidism cause reduced bone mineral density (BMD) in female patients with AD. This may […]
Palliative assessment and advance care planning in severe dementia: an exploratory randomized controlled trial of a complex intervention
Sampson, Elizabeth L.,
Jones, Louise,
Thuné-Boyle, Ingela C. V.,
Kukkastenvehmas, Riitta,
King, Michael,
Leurent, Baptiste,
Tookman, Adrian,
Blanchard, Martin R.
Patients with advanced dementia often receive poor end-of-life care. We aimed to design and pilot a palliative care and advance care plan (ACP) intervention. Patients had undergone emergency hospital admission and had severe dementia. The intervention consisted of a palliative care patient assessment which informed an ACP discussion with the carer, who was offered the […]
Health and nutrition promotion program for patients with dementia (NutriAlz): cluster randomized trial
Salva, A.,
Andrieu, S.,
Fernandez, E.,
Schiffrin, E. J.,
Moulin, J.,
Decarli, B.,
Rojano-i-Luque, X.,
Guigoz, Y.,
Vellas, B.
Objective: To assess the effectiveness of health and nutrition program (NutriAlz) versus usual care on functional level in elderly people with dementia living at home, as well as on clinical practice related to nutrition and on the caregiver’s burden.; Design: Cluster randomized multi-centre study with one-year follow-up.; Setting: 11 Alzheimer outpatients and day care centres […]
Cognitive training changes hippocampal function in mild cognitive impairment: a pilot study
A randomized pilot experiment examined the neural substrates of response to cognitive training in participants with mild cognitive impairment (MCI). Participants performed exercises previously demonstrated to improve verbal memory and an active control group performed other computer activities. An auditory-verbal fMRI task was conducted before and after the two-month training program. Verbal memory scores improved […]
A phase II trial of huperzine A in mild to moderate Alzheimer disease
Rafii, M. S.,
Walsh, S.,
Little, J. T.,
Behan, K.,
Reynolds, B.,
Ward, C.,
Jin, S.,
Thomas, R.,
Aisen, P. S.
Objective: Huperzine A is a natural cholinesterase inhibitor derived from the Chinese herb Huperzia serrata that may compare favorably in symptomatic efficacy to cholinesterase inhibitors currently in use for Alzheimer disease (AD).; Methods: We assessed the safety, tolerability, and efficacy of huperzine A in mild to moderate AD in a multicenter trial in which 210 […]